Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial

BackgroundThe phase-II modafinil in debilitating fatigue after stroke trial demonstrated that modafinil improves fatigue and quality of life in severely fatigued stroke survivors. For this study, we sought to examine the interaction between fatigue and quality of life after stroke and determine whet...

Full description

Bibliographic Details
Main Authors: Thomas P. Lillicrap, Christopher R. Levi, Elizabeth Holliday, Mark William Parsons, Andrew Bivard
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-04-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2018.00269/full
id doaj-fc76467d7c044e76999c37f25b83c35e
record_format Article
spelling doaj-fc76467d7c044e76999c37f25b83c35e2020-11-24T22:58:01ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-04-01910.3389/fneur.2018.00269362258Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke TrialThomas P. Lillicrap0Thomas P. Lillicrap1Christopher R. Levi2Christopher R. Levi3Elizabeth Holliday4Mark William Parsons5Mark William Parsons6Andrew Bivard7Andrew Bivard8Neurology Department, John Hunter Hospital, Newcastle, NSW, AustraliaHunter Medical Research Institute, Newcastle, NSW, AustraliaNeurology Department, John Hunter Hospital, Newcastle, NSW, AustraliaHunter Medical Research Institute, Newcastle, NSW, AustraliaHunter Medical Research Institute, Newcastle, NSW, AustraliaNeurology Department, John Hunter Hospital, Newcastle, NSW, AustraliaHunter Medical Research Institute, Newcastle, NSW, AustraliaNeurology Department, John Hunter Hospital, Newcastle, NSW, AustraliaHunter Medical Research Institute, Newcastle, NSW, AustraliaBackgroundThe phase-II modafinil in debilitating fatigue after stroke trial demonstrated that modafinil improves fatigue and quality of life in severely fatigued stroke survivors. For this study, we sought to examine the interaction between fatigue and quality of life after stroke and determine whether reducing fatigue resulted in improved quality of life. In addition, we followed up a subset of patients 12-months after the trial to assess the long-term outcomes of modafinil therapy.MethodsWe used linear regression to analyze interaction between baseline fatigue, as measured by the multidimensional fatigue inventory (MFI), and quality of life, as measured by the stroke-specific quality of life scale (SSQoL); and between changes in MFI and SSQoL during treatment. Patients also took part in semi-structured interviews and study assessments 12-months after trial completion to assess long-term patterns of modafinil use, safety and efficacy.ResultsMFI and SSQoL were significantly correlated at baseline (β = −1.975 95% CI −3.082, −0.869, p < 0.001), as were changes in MFI and SSQoL during treatment (β = −1.054 95% CI −1.556, −0.553, p < 0.001). 18 patients agreed to 12-month follow-up, of whom 5 had continued to use modafinil. Patients taking modafinil daily demonstrated sustained improvement of 33–38 points in MFI compared to baseline. Two adverse events were reported and there was no evidence of drug tolerance.ConclusionModafinil appears to be safe and, for at least some patients, effective long-term in fatigued stroke survivors. Alleviating fatigue has a significant relationship with improved quality of life.Clinical trial registrationhttps://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368268, unique-identifier: ACTRN12615000350527.http://journal.frontiersin.org/article/10.3389/fneur.2018.00269/fullstrokestroke recoveryfatiguemodafinilquality of life
collection DOAJ
language English
format Article
sources DOAJ
author Thomas P. Lillicrap
Thomas P. Lillicrap
Christopher R. Levi
Christopher R. Levi
Elizabeth Holliday
Mark William Parsons
Mark William Parsons
Andrew Bivard
Andrew Bivard
spellingShingle Thomas P. Lillicrap
Thomas P. Lillicrap
Christopher R. Levi
Christopher R. Levi
Elizabeth Holliday
Mark William Parsons
Mark William Parsons
Andrew Bivard
Andrew Bivard
Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
Frontiers in Neurology
stroke
stroke recovery
fatigue
modafinil
quality of life
author_facet Thomas P. Lillicrap
Thomas P. Lillicrap
Christopher R. Levi
Christopher R. Levi
Elizabeth Holliday
Mark William Parsons
Mark William Parsons
Andrew Bivard
Andrew Bivard
author_sort Thomas P. Lillicrap
title Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
title_short Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
title_full Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
title_fullStr Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
title_full_unstemmed Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
title_sort short- and long-term efficacy of modafinil at improving quality of life in stroke survivors: a post hoc sub study of the modafinil in debilitating fatigue after stroke trial
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2018-04-01
description BackgroundThe phase-II modafinil in debilitating fatigue after stroke trial demonstrated that modafinil improves fatigue and quality of life in severely fatigued stroke survivors. For this study, we sought to examine the interaction between fatigue and quality of life after stroke and determine whether reducing fatigue resulted in improved quality of life. In addition, we followed up a subset of patients 12-months after the trial to assess the long-term outcomes of modafinil therapy.MethodsWe used linear regression to analyze interaction between baseline fatigue, as measured by the multidimensional fatigue inventory (MFI), and quality of life, as measured by the stroke-specific quality of life scale (SSQoL); and between changes in MFI and SSQoL during treatment. Patients also took part in semi-structured interviews and study assessments 12-months after trial completion to assess long-term patterns of modafinil use, safety and efficacy.ResultsMFI and SSQoL were significantly correlated at baseline (β = −1.975 95% CI −3.082, −0.869, p < 0.001), as were changes in MFI and SSQoL during treatment (β = −1.054 95% CI −1.556, −0.553, p < 0.001). 18 patients agreed to 12-month follow-up, of whom 5 had continued to use modafinil. Patients taking modafinil daily demonstrated sustained improvement of 33–38 points in MFI compared to baseline. Two adverse events were reported and there was no evidence of drug tolerance.ConclusionModafinil appears to be safe and, for at least some patients, effective long-term in fatigued stroke survivors. Alleviating fatigue has a significant relationship with improved quality of life.Clinical trial registrationhttps://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368268, unique-identifier: ACTRN12615000350527.
topic stroke
stroke recovery
fatigue
modafinil
quality of life
url http://journal.frontiersin.org/article/10.3389/fneur.2018.00269/full
work_keys_str_mv AT thomasplillicrap shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT thomasplillicrap shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT christopherrlevi shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT christopherrlevi shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT elizabethholliday shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT markwilliamparsons shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT markwilliamparsons shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT andrewbivard shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
AT andrewbivard shortandlongtermefficacyofmodafinilatimprovingqualityoflifeinstrokesurvivorsaposthocsubstudyofthemodafinilindebilitatingfatigueafterstroketrial
_version_ 1725648726744104960